On Monday, Baidu Inc (ADR) (NASDAQ:BIDU)’s shares inclined 0.44% to $176.85.
Baidu, Inc. (BIDU) the leading Chinese language Internet search provider, recently declared that its board of directors has authorized a share repurchase program under which the Company may repurchase up to US$1 billion of its shares over the next 12 months.
The Company’s projected repurchases may be made from time to time on the open market at prevailing market prices, in privately negotiated transactions, in block trades and/or through other legally permissible means, depending on market conditions and in accordance with applicable rules and regulations. The Company’s board of directors will review the share repurchase program periodically, and may authorize adjustment of its terms and size. The Company plans to fund repurchases from its existing cash balance.
Baidu, Inc. provides Internet search services in China and internationally. It offers Chinese language search platform on its Baidu.com Website that enables users to find relevant information online, counting Web pages, news, images, documents, and multimedia files through links offered on its Website; and international products and services to users in other countries.
Expedia Inc (NASDAQ:EXPE)’s shares gained 0.37% to $121.49.
Expedia Inc (EXPE) declared the results of a collaborative study to determine how travel and romance intersect for Americans. The 2015 Foreign Affairs Study was commissioned by Expedia® and Tinder and conducted by GfK, an independent global market research company.
GfK asked 1,000 Americans a range of questions about travel and romance, counting how early in a relationship they would consider taking an overnight vacation, which destination features they would prioritize on their first trip away, how willing they would be to vacation with a partner’s parents and where the most attractive dating populations reside.
The full Expedia/Tinder 2015 Foreign Affairs Study can be found here on the Expedia® Viewfinder blog. In addition to this, Expedia and Tinder also launched a Match Made in Travel game that allows users to swipe right on their favorite locations and get paired with their ideal destination match. Check out the game here.
Expedia, Inc., together with its auxiliaries, operates as an online travel company in the United States and internationally. The company operates in two segments, Leisure and Egencia. It provides travel products and services to leisure and corporate travelers, offline retail travel agents, and travel service providers through a portfolio of brands, counting Expedia.com, Hotels.com, Hotwire.com, Classic Vacations, Travelocity, Expedia Local Expert, Egencia, Expedia CruiseShipCenters, eLong, and Venere.com, in addition to trivago, CarRentals.com, Wotif.com, lastminute.com.au, travel.com.au, Asia Web Direct, LateStays.com, GoDo.com.au, and Arnold Travel Technology.
At the end of Monday’s trade, Biomed Realty Trust Inc (NYSE:BMR)‘s shares dipped -0.57% to $20.76.
BioMed Realty Trust, Inc. (BMR), investing in the highest quality institutional real estate to meet growing demand across the life science industry, stated funds from operations (FFO) and core FFO (CFFO) per diluted share of $0.58 for the second quarter ended June 30, 2015, driven by the company’s strong leasing, development deliveries, and investment acumen over the past four quarters.
The company’s unique platform, anchored by a deep team of life science real estate professionals, delivered a new record for gross leasing in the quarter with 1.3 million square feet led by new leases with Eli Lilly and Alnylam Pharmaceuticals in Cambridge, Massachusetts, Regeneron Pharmaceuticals in New York, and Illumina in Cambridge, United Kingdom, in addition to leases to top tier research institutions Duke University and Wake Forest University. Total gross leasing in the second quarter resulted in about 218,400 square feet of positive net absorption in the operating portfolio and an additional 370,300 square feet of absorption across the company’s development portfolio.
BioMed Realty Trust, Inc. operates as a real estate investment trust (REIT) that focuses on providing real estate to the life science industry in the United States. Its tenants primarily comprise biotechnology and pharmaceutical companies, scientific research institutions, government agencies, and other entities involved in the life science industry. The company owns or has interests in 72 properties, representing 119 buildings with about 11.0 million rentable square feet. Its properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania, and New York/New Jersey. The company qualifies as a REIT for federal income tax purposes.
Sangamo Biosciences, Inc. (NASDAQ:SGMO), ended its Monday’s trading session with 1.55% gain, and closed at $7.84.
Sangamo BioSciences, Inc. (SGMO) stated its second quarter 2015 financial results and accomplishments.
For the second quarter ended June 30, 2015, Sangamo stated a merged net loss of $12.1 million, or $0.17 per share, contrast to a net loss of $7.0 million, or $0.10 per share, for the same period in 2014. As of June 30, 2015, the Company had cash, cash equivalents, marketable securities and interest receivable of $218.6 million.
Revenues for the second quarter of 2015 were $8.4 million, contrast to $10.4 million for the same period in 2014. Second quarter 2015 revenues were generated from the Company’s partnership agreements with Shire International GmbH (Shire), Biogen Inc. (Biogen), enabling technology agreements and research grants. The revenues recognized for the second quarter of 2015 comprised of $7.8 million in partnership agreements and $0.6 million in research grants, contrast to $9.7 million and $0.7 million, respectively, for the same period in 2014.
Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focused on the research, development, and commercialization of engineered DNA-binding proteins as novel therapeutic products for various monogenic and infectious diseases with unmet medical needs. Its proprietary zinc finger DNA-binding protein (ZFP) technology enables precise and highly specific genome modification and gene regulation.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
